STAT Plus: As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches
As the U.S. grapples with rising costs for prescription medicines, the Trump administration has floated…
Category: Pharma
Purdue’s Richard Sackler proposed plan to play down OxyContin risks, and wanted drug maker feared ‘like a tiger,’ files show
PIKEVILLE, Ky. — In the early days of OxyContin, Dr. Richard Sackler, a member of…
STAT Plus: Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast
Good morning, everyone, an welcome to another working week. We hope the weekend respite, which…
STAT Plus: Biogen will offer discounts to a health plan if patients say its multiple sclerosis drugs don’t work
In a twist on value-based contracting, a drug maker has agreed to offer a larger…
STAT Plus: Pharmalittle: Feds probe drug makers for flooding communities with opioids; States proceeding with importation
And so, another working week will soon come to an end, but earlier than usual,…
STAT Plus: EMA adopts EU Ombudsman recommendations to avoid bias concerns over drug approvals
Seeking to end another flap about transparency, the European Medicines Agency has agreed to recommendations…
STAT Plus: Pharmalittle: Generic makers talk to feds about ending price-fixing probe; how the Arnolds fueled the pricing debate in D.C.
Hello, everyone, and how are you today? We are doing just fine, thank you, now…
STAT Plus: Pharma execs tell researchers that multiple sclerosis drug pricing is based on competition, not R&D costs
Despite claims that prices for new medicines are generally shaped by R&D costs, initial pricing…
STAT Plus: Merck is probed by Spain’s antitrust regulator for allegedly delaying competition for a contraceptive
The antitrust regulator in Spain has accused Merck (MRK) of working with other companies to…
STAT Plus: Generic trade group sues California for an ‘unconstitutional’ law banning pay-to-delay deals
A newly enacted California law that bans so-called pay-to-delay deals between drug makers would reduce…
STAT Plus: Pharmalittle: Novartis to pay $9.7 billion for The Medicines Co.; Trump bashes Pelosi drug pricing bill
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
With $9.7 billion acquisition, Novartis bets that heart drugs are coming back
Novartis’ $9.7 billion acquisition of The Medicines Company, which the companies announced Sunday after days…
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
CAMBRIDGE, Mass. — In his first appearance since Bristol-Myers Squibb completed its takeover last week…
STAT Plus: A bold prediction: Machine learning will yield new drug candidates within three years
CAMBRIDGE, Mass. — An explosion of biological data will lead to the first drug candidates…
STAT Plus: Pharmalittle: Trump and senators push for drug prices in TV ads; Sanofi looks to spin off consumer business
Top of the morning to you, and a fine one it is. We may have…
STAT Plus: Patient charity settles allegations it helped MS drug makers pay kickbacks
A patient assistance charity has agreed to pay $4 million to settle allegations that it…
STAT Plus: Pharmalittle: Purdue affiliate in China pushes misleading opioid claims; more generics are approved but not yet available
Hello, everyone, and nice to see you again after a brief sojourn in a foreign…
OxyContin maker thrives in China with abandoned U.S. tactics
SHANGHAI — OxyContin is a dying business in the United States. Purdue Pharma, owned by…
STAT Plus: Pharmalittle: How Purdue planted its ‘anti-story’; how much does that ‘free’ flu shot cost?
Good morning. Elizabeth Cooney here again in Boston while Ed Silverman completes another engagement abroad….
How Purdue planted its ‘anti-story’ and delayed the reckoning for its role in the opioid epidemic
This story is a collaboration between STAT and ProPublica. In 2004, Purdue Pharma was facing…